Breaking News
Get 45% Off 0
🚨 Don’t miss your updated list of AI-picked stocks for this month
Pick Stocks with AI

Aetna, CVS Health Ink A Merger Agreement Worth $69 Billion

By Zacks Investment ResearchStock MarketsDec 03, 2017 08:25PM ET
www.investing.com/analysis/aetna-cvs-health-ink-a-merger-agreement-worth-69-billion-200270262
Aetna, CVS Health Ink A Merger Agreement Worth $69 Billion
By Zacks Investment Research   |  Dec 03, 2017 08:25PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
AET
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CVS
+1.92%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
UNH
+1.37%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GTS
+0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Aetna Inc. (NYSE:AET) will soon be acquired by CVS Health Corp. (NYSE:CVS) , per a definitive merger agreement.

This mega-merger between a pharmacy health care provider, CVS and an insurance company, Aetna, is expected to close in the second half of 2018. Valued at nearly $69 billion, the deal is subject to approval by shareholders of both the companies, regulatory approvals and other customary closing conditions.

Notably, the merger-agreement has a greater probability of getting an approval from the regulators since it will be a vertical integration as compared to the horizontal combination (which was feared to create a monopoly in the market and stifle healthy competition among rivals, if passed) of Aetna-Humana Inc. (HUM) deal, which was inked earlier this year.

Additionally, the deal seems to be encouraging as it would result in a deadly combination of Aetna’s strong position and its expertise in the health benefits space coupled with CVS’ deep knowledge of the consumers and its leading position in the pharmacy benefits market.

This combined entity is anticipated to create a mammoth healthcare set-up with wide-ranging operations from sale of drug to insurance cover.

What’s in Store for Aetna?

The deal will add to Aetna’s scale and size, and equip it to negotiate with drug manufacturers and pharmacies in a better way. Consequently, this would lower the cost of acquiring prescription drugs, thereby enabling the company to share the savings with its consumers through more customer-friendly insurance plans like enhanced frills or lower premium. This, in turn, might ultimately lead to market-share gain.

So far this year, the stock has surged 45%, outperforming the industry’s growth of 42%.



Gain for Shareholders

Aetna shareholders will receive attractive value from the transaction, including $145 per share in cash and 0.8378 shares of CVS Health common stock. Also, approximately 22% of the combined company will be owned by them. Consequently, these shareholders will be able to be a part of the success and high growth potential of the combined company in the near term.

Shareholders will benefit from deal which should result in enhanced competitive positioning, low- to mid-single digit accretion in 2019 including the ability to deliver $750 million in near-term synergies.

Consolidation in the Health Care Space

Mergers and acquisition (both horizontal and vertical) in the space is rife, given the necessity of the players to gain in scale and size to weather the changes taking place within the industry. Such deals (pharmacy benefit managers with insurance companies) are the need of the hour at the backdrop of a changing industry, which is rapidly seeing a rise in consumerism.

Also, the increased incidence of specialty drugs that are paid through medical and not pharmacy benefit organizations, necessitates the coming together of medical and pharmacy benefit companies.

The takeover of Catamaran by UnitedHealth Group Inc. (NYSE:UNH) back in 2015 was in line with this trend.

Zacks Rank and Stocks to Consider

Aetna carries a Zacks Rank #3 (Hold). A better-ranked stock in the same space is Triple-S Management Corp. (NYSE:GTS) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Triple-S Management pulled off positive surprises in two of the trailing four quarters with an average beat of 74%.

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.

Click here for Zacks' private trades >>



Aetna Inc. (AET): Free Stock Analysis Report

UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report

Triple-S Management Corporation (GTS): Free Stock Analysis Report

CVS Health Corporation (CVS): Free Stock Analysis Report

Original post

Zacks Investment Research

Aetna, CVS Health Ink A Merger Agreement Worth $69 Billion
 

Related Articles

Aetna, CVS Health Ink A Merger Agreement Worth $69 Billion

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email